Anbio Biotechnology (NASDAQ:NNNN – Get Free Report)’s share price fell 8.2% on Wednesday . The stock traded as low as $12.60 and last traded at $12.5830. Approximately 7,772 shares were traded during trading, a decline of 83% from the average session volume of 44,722 shares. The stock had previously closed at $13.71.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.
Check Out Our Latest Stock Report on NNNN
Anbio Biotechnology Price Performance
Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) last issued its quarterly earnings data on Tuesday, April 7th. The company reported $0.03 earnings per share (EPS) for the quarter.
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
- Five stocks we like better than Anbio Biotechnology
- Why Kroger’s Giant Eagle Deal Could Change Everything
- Why the Comcast Spin-Off Won’t Fix What’s Actually Broken
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
